...
首页> 外文期刊>The American Journal of Tropical Medicine and Hygiene >Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia.
【24h】

Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia.

机译:单纯性恶性疟疾的治疗:一项在印度尼西亚伊里安再也比较青蒿琥酯加磺胺多辛-乙胺嘧啶与单独磺胺多辛-乙胺嘧啶的随机试验。

获取原文
获取原文并翻译 | 示例

摘要

Combining artesunate with existing antimalarial drugs may improve cure rates, delay emergence of resistance, and reduce transmission. We performed a randomized comparative trial to quantify the effect of adding artesunate to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in Indonesia. Using a modified 1997 World Health Organization protocol for assessment of therapeutic efficacy of antimalarial drugs, 105 patients (stratified by age/ethnic group) were randomized: 53 received artesunate orally, 4 mg/kg of body weight, a single daily dose for three days, plus sulfadoxine-pyrimethamine orally (1.25 mg of pyrimethamine/kg of body weight), a single dose on day 0, and 52 patients received sulfadoxine-pyrimethamine alone. Six from the combination group were withdrawn from analysis, as were six of the sulfadoxine-pyrimethamine group. Treatment failure rates on day 14 were 0% in the artesunate plus sulfadoxine-pyrimethamine group and 8.7% in the sulfadoxine-pyrimethamine group (P = 0.12). Treatment failure rates on day 28 were 4.4% and 15.2%, respectively (P = 0.16). Relative risk of treatment failure at 28 days was 0.3 (95% confidence interval [CI] = 0.1-1.3). Mean fever clearance time (1.3 versus 1.7 days) and mean parasite clearance time (1.4 versus 2.0 days) were both faster in the artesunate plus sulfadoxine-pyrimethamine group than in the sulfadoxine-pyrimethamine group (P = 0.08 and P < 0.0001, respectively). Only 20 (39.2%) of 51 patients treated with artesunate plus sulfadoxine-pyrimethamine were still parasitemic on day 1 compared with 45 (86.5%) of 52 patients treated with sulfadoxine-pyrimethamine alone (P = 0.000001, relative risk [RR] = 0.4, 95% CI = 0.3-0.6). Gametocyte carriage was lower following artesunate plus sulfadoxine-pyrimethamine than following sulfadoxine-pyrimethamine (RR = 0.5, 95% CI = 0.2-1.0 on day 7 and RR = 0.5, 95% CI = 0.2-1.1 on day 14). Mild diarrhea, rash, and itching resolved without treatment. Combined artesunate plus sulfadoxine-pyrimethamine resulted in more rapid fever and parasiteclearance, was well tolerated, reduced risk of treatment failure, and lowered gametocyte carriage.
机译:青蒿琥酯与现有抗疟药合用可提高治愈率,延缓耐药性的出现并减少传播。我们进行了一项随机对照试验,以量化在磺胺多辛-乙胺嘧啶中添加青蒿琥酯对印尼单纯性恶性疟疾的治疗效果。使用经修订的1997年世界卫生组织协议评估抗疟药的疗效,将105例患者(按年龄/种族分组)随机分组:口服青蒿琥酯53例,体重4 mg / kg,每日一次,三天,口服磺胺多辛-乙胺嘧啶(1.25 mg乙胺嘧啶/ kg体重),在第0天单剂,52例患者单独接受磺胺多辛-乙胺嘧啶。联合治疗组中的六个被撤出,磺胺多辛-乙胺嘧啶组中的六个被撤出分析。青蒿琥酯加磺胺多辛-乙胺嘧啶组第14天的治疗失败率为0%,磺胺多辛-乙胺嘧啶组为8.7%(P = 0.12)。第28天的治疗失败率分别为4.4%和15.2%(P = 0.16)。 28天治疗失败的相对风险为0.3(95%置信区间[CI] = 0.1-1.3)。青蒿琥酯加磺胺多辛-乙胺嘧啶组的平均发烧清除时间(1.3天为1.7天)和寄生虫的平均清除时间(1.4天与2.0天)均快于磺胺多辛-乙胺嘧啶组(分别为P = 0.08和P <0.0001) 。在第1天,接受青蒿琥酯联合磺胺多辛-乙胺嘧啶治疗的51例患者中只有20(39.2%)仍然是寄生虫,相比之下,单独使用磺胺多辛-乙胺嘧啶治疗的52例患者中有45(86.5%)(P = 0.000001,相对风险[RR] = 0.4 ,95%CI = 0.3-0.6)。青蒿琥酯+磺胺多辛-乙胺嘧啶后的配子细胞运输低于磺胺多辛-乙胺嘧啶后(第7天RR = 0.5,95%CI = 0.2-1.0,第14天RR = 0.5,95%CI = 0.2-1.1)。轻度腹泻,皮疹和瘙痒无需治疗即可解决。青蒿琥酯与磺胺多辛-乙胺嘧啶合用可导致更快的发烧和寄生虫清除,耐受性良好,降低治疗失败的风险,并降低配子细胞的转运。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号